Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$49.75 USD
+1.97 (4.12%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $49.79 +0.04 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for Kymera Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -146.96 | -154.81 | -100.22 | -45.59 | -41.25 |
Depreciation/Amortization & Depletion | -1.66 | 3.87 | 8.20 | 3.33 | 0.83 |
Net Change from Assets/Liabilities | 2.68 | -37.62 | -61.92 | 124.87 | 56.69 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 43.12 | 35.48 | 24.99 | 5.52 | 1.64 |
Net Cash From Operating Activities | -102.83 | -153.09 | -128.95 | 88.13 | 17.91 |
Property & Equipment | -34.48 | -2.84 | -1.60 | -9.10 | -0.53 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 174.37 | 23.36 | -98.24 | -413.49 | -15.95 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 139.89 | 20.52 | -99.84 | -422.59 | -16.49 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.86 | 152.98 | 250.74 | 276.29 | 35.28 |
Issuance (Repayment) of Debt | -0.08 | -1.13 | -0.85 | -0.55 | -0.37 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 1.41 | 1.15 | 0.39 | 13.53 | 0.00 |
Net Cash from Financing Activities | 4.19 | 153.00 | 250.28 | 289.26 | 34.91 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 41.25 | 20.43 | 21.50 | -45.20 | 36.33 |
Cash at Beginning of Period | 74.53 | 54.09 | 32.59 | 77.79 | 41.46 |
Cash at End of Period | 115.78 | 74.53 | 54.09 | 32.59 | 77.79 |
Diluted Net EPS | -2.52 | -2.87 | -2.09 | -3.15 | NA |
Fiscal Year End for Kymera Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -90.62 | -48.56 | -146.96 | -132.59 | -79.73 |
Depreciation/Amortization & Depletion | -3.69 | -1.61 | -1.66 | -1.29 | -0.96 |
Net Change from Assets/Liabilities | -19.45 | -6.32 | 2.68 | -9.21 | -19.10 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 31.23 | 16.89 | 43.12 | 32.22 | 20.57 |
Net Cash From Operating Activities | -82.53 | -39.59 | -102.83 | -110.87 | -79.22 |
Property & Equipment | -12.09 | -7.40 | -34.48 | -22.86 | -14.78 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -302.87 | -323.21 | 174.37 | 143.79 | 75.20 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -314.97 | -330.61 | 139.89 | 120.93 | 60.42 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 354.68 | 354.05 | 2.86 | 2.30 | 2.16 |
Issuance (Repayment) of Debt | -0.64 | -0.29 | -0.08 | -1.00 | -0.66 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 1.14 | 0.00 | 1.41 | 0.96 | 0.96 |
Net Cash from Financing Activities | 355.17 | 353.76 | 4.19 | 2.26 | 2.46 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -42.32 | -16.44 | 41.25 | 12.32 | -16.34 |
Cash at Beginning of Period | 115.78 | 115.78 | 74.53 | 74.52 | 74.52 |
Cash at End of Period | 73.45 | 99.34 | 115.78 | 86.85 | 58.19 |
Diluted Net EPS | -0.58 | -0.69 | -0.25 | -0.90 | -0.67 |